STOCK TITAN

Nuo Therapeutics Q3 2026 revenue rises to $1.87M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. (AURX) reported third-quarter 2026 revenue of $1,866,125, compared with $1,032,096 a year earlier, and a net loss of $424,928 versus $537,919. For the first nine months of 2026, revenue was $4,937,226 compared with $2,216,679, while net loss was $1,320,995 versus $1,933,736. Cash was $80,941 at September 30, 2026, compared with $548,946 at December 31, 2025.

Nuo said Aurix revenue in the hospital setting reached its highest quarterly level ever. HOPD Aurix sales as a share of total wound care sales had more than doubled since the first quarter. The company said final 2027 Medicare rulings left unchanged the January reimbursement-economics change for skin substitutes/grafts. Nuo is prioritizing reaching the revenue level required for operational breakeven and assessing ways to strengthen its capital structure; secured notes under the loan agreement were funded in several tranches this year.

4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointQuarterly revenue: $1,866,125, versus $1,032,096 a year earlier.
  • Moderate pointQuarterly net loss: $424,928, versus $537,919 in Q3 2025.
  • Minor pointNine-month revenue: $4,937,226, versus $2,216,679 in 2025.
  • Minor pointNine-month net loss: $1,320,995, versus $1,933,736 in 2025.

Negative

  • None.

Filing Explained

At September 30, 2026, cash of 80,941 dollars equaled 38.3 days of third-quarter operating cash outflow at that quarter’s rate.

The 8-K furnishes Nuo Therapeutics’ third-quarter and first-nine-month 2026 results and business update. At September 30, 2026, its balance sheet lists $515,625 of current and $961,875 of noncurrent notes payable, plus $112,500 of current and $210,500 of noncurrent related-party notes.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $80,941 / ($194,604 / 92) = 38.3 days
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter total revenue $1,866,125 Three months ended September 30, 2026; compared with $1,032,096 for the same period in 2025.
Third-quarter net loss $424,928 Three months ended September 30, 2026; compared with $537,919 for the same period in 2025.
Nine-month total revenue $4,937,226 Nine months ended September 30, 2026; compared with $2,216,679 for the same period in 2025.
Nine-month net loss $1,320,995 Nine months ended September 30, 2026; compared with $1,933,736 for the same period in 2025.
Cash $80,941 As of September 30, 2026; cash was $548,946 as of December 31, 2025.
HOPD medical
"HOPD Aurix sales as a percentage of total wound care sales"
autologous PRP medical
"autologous PRP and Aurix in particular"
biodynamic hematogel medical
"Aurix System is a biodynamic hematogel"
skin substitutes/grafts medical
"reimbursement economics for skin substitutes/grafts"
Medicare reimbursement regulatory
"final 2027 rulings mentioned above"
Medicare reimbursement is the payment a government health insurance program makes to hospitals, doctors, drugmakers and device makers for covered treatments, drugs or services. Think of it as the price a very large customer agrees to pay a seller; the level and timing of those payments influence how much revenue a health company can earn, how it prices products, and how quickly new treatments are adopted, so changes in reimbursement often directly affect investor returns and risk.
secured notes financial
"funding of the secured notes under the loan agreement"
Secured notes are loans issued as tradable bonds that are tied to specific assets—like a mortgage is tied to a house—so if the borrower can’t pay, holders have a legal claim on that collateral. For investors this usually means lower risk and higher chance of recovering money in a default, but returns tend to be smaller than for unsecured debt and the real safety depends on the value and legal strength of the pledged assets.
Third-quarter total revenue $1,866,125 Compared with $1,032,096 for the three months ended September 30, 2025.
Third-quarter net loss $424,928 Compared with $537,919 for the three months ended September 30, 2025.
Nine-month total revenue $4,937,226 Compared with $2,216,679 for the nine months ended September 30, 2025.
Nine-month net loss $1,320,995 Compared with $1,933,736 for the nine months ended September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did AURX report in the third quarter of 2026?

AURX reported total revenue of $1,866,125 for the three months ended September 30, 2026, compared with $1,032,096 in the prior-year quarter. For the first nine months of 2026, total revenue was $4,937,226, versus $2,216,679 in 2025.

What was AURX's net loss in the third quarter and first nine months of 2026?

AURX reported a third-quarter net loss of $424,928, compared with $537,919 for Q3 2025. For the first nine months of 2026, net loss was $1,320,995, compared with $1,933,736 for the same period in 2025.

What did AURX say about its secured notes and capital structure?

Nuo said secured notes under its loan agreement were funded in several tranches this year. It said its priorities include reaching the revenue level required for operational breakeven and assessing opportunities to strengthen its capital structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001091596 0001091596 2026-11-16 2026-11-16
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): November 16, 2026
 
Nuo Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
 
Delaware
000-28443
23-3011702
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
 
8285 El Rio, Suite 190, Houston, Texas 77054
(Address of principal executive offices) (Zip Code)
 
(346) 396-4770
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
 
Securities registered pursuant to Section 12(b) of the Act: None
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 

 
 
Item 2.02 Results of Operations and Financial Condition
 
On November 16, 2026, Nuo Therapeutics, Inc. (“Nuo”) issued a press release announcing its financial results for the third quarter and first nine months of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference.
 
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
 
 
Item 9.01 Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit No.
Description
99
Press Release of Nuo Therapeutics, Inc. dated November 16, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Nuo Therapeutics, Inc.
 
       
       
 
By:  
/s/ David E. Jorden
 
   
David E. Jorden
 
   
Chief Executive and Chief Financial Officer
 
 
Date: November 17, 2026
 
 

Exhibit 99

 

 

logo01.jpg

8285 El Rio, Suite 190

Houston, TX 77054

Phone 833.298.6633

 

 

 

NUO THERAPEUTICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

 

Final 2027 Medicare Reimbursement Rulings and Coverage Expansion to New Place of Service Reinforce Growth Outlook

 

Houston, TX – November 16, 2026 – Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the third quarter ended September 30, 2026 and provided an operational and business update.

 

Third Quarter and First Nine Months 2026 Financial Summary

 

 

●

Total revenues of approximately $1.9 million and $4.9 million for the third quarter 2026 and first nine months of 2026, respectively, increased 80% and 123%, respectively, versus the comparable 2025 periods.

 

●

Total product revenues in the third quarter increased 5% sequentially versus the second quarter 2026 with Aurix wound care revenues increasing approximately 17% sequentially which is the same average sequential growth rate over the past six quarters for Aurix wound care revenues.

 

●

Third quarter net operating loss of approximately $374,000 improved by approximately $166,000 compared to third quarter 2025 while increasing approximately $208,000 sequentially versus the second quarter. The sequential increase primarily reflected higher stock-based compensation, credit loss provision expense, and more than $100,000 of elevated regulatory costs associated with component supply matters.

 

●

Subsequent to quarter end, final funding of $325,000 was received under the loan agreement with total borrowings established at $2,000,000.

 

Operational and Business Update

 

 

●

Received $250,000 reimbursement fee milestone pursuant to the 2025 distribution agreement with Smith+Nephew.

 

●

Final Medicare OPPS (Outpatient Prospective Payment System) reimbursement ruling recently released for calendar 2027 with the per treatment G0465 national average reimbursement increasing to approximately $2,257 or 7% from 2026 with positive pricing actions for Aurix anticipated next year.

 

●

Medicare’s PFS (Physician Fee Schedule) ruling established a G0465 national average reimbursement of approximately $1,020 in 2027 or a decrease of approximately 4%.

 

●

Expansion of coverage and processing of G0465 claims for nursing home treatments (Medicare Place of Service 32) effective January 1, 2027 is expected to be positive for future growth.

 

 

 

“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above,” commented David Jorden, Nuo’s Chief Executive and Financial Officer.

 

“We have also observed a shift of patients and wound care volumes back to hospital-based settings and enjoyed our highest quarter ever of Aurix revenues in the hospital setting,” continued Mr. Jorden. “Since this year’s first quarter, our HOPD Aurix sales as a percentage of total wound care sales has more than doubled. The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment. We remain confident that autologous PRP and Aurix in particular are well positioned for continued long term attractive growth.”

 

“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth. The funding of the secured notes under the loan agreement in several tranches this year was done with these priorities in mind,” concluded Mr. Jorden.

 

About Nuo Therapeutics

 

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, including in the hospital outpatient setting, expectations regarding Medicare reimbursement and coverage changes, including the expansion of coverage to nursing home treatments, and their impact on demand for and pricing of Aurix, anticipated pricing actions, movement toward breakeven operations, and Nuo's ability to strengthen its capital structure. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

 

 

Contact:

David Jorden

 

 

 

NUO THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   

September 30,

2026

   

December 31,

2025

 

ASSETS

               

Current assets

               

Cash

  $ 80,941     $ 548,946  

Accounts receivable, net

    1,410,322       561,667  

Inventory, net

    330,134       213,761  

Prepaid expenses and other current assets

    162,667       55,509  

Total current assets

    1,984,064       1,379,883  
                 

Property and equipment, net

    704,903       366,315  

Operating lease right of use assets

    41,238       99,464  

Total assets

  $ 2,730,205     $ 1,845,662  
                 

LIABILITIES AND STOCKHOLDERS' DEFICIT

               

Current liabilities

               

Accounts payable

  $ 756,720     $ 436,083  

Accrued expenses

    648,177       493,792  

Deferred revenue

    380,730       300,000  

Current portion of notes payable

    515,625       -  

Current portion of notes payable – related party

    112,500       -  

Current portion of operating lease liabilities

    40,756       76,410  

Total current liabilities

    2,454,508       1,306,285  
                 

Deferred revenue – long term

    951,826       975,000  

Notes payable

    961,875       300,000  

Note payable – related party

    210,500       200,000  

Non-current portion of operating lease liabilities

    -       20,936  

Total liabilities

    4,578,709       2,802,221  
                 

Stockholders' deficit

               

Common stock; $0.0001 par value, 100,000,000 shares authorized, 48,573,894 and 48,179,039 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively

    4,857       4,818  

Additional paid-in capital

    34,239,796       33,810,785  

Accumulated deficit

    (36,093,157 )     (34,772,162 )

Total stockholders' deficit

    (1,848,504 )     (956,559 )
                 

Total liabilities and stockholders' deficit

  $ 2,730,205     $ 1,845,662  

 

 

 

NUO THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   

Three Months

ended

September 30,

2026

   

Three Months

ended

September 30,

2025

 

Revenue

               

Product sales

  $ 1,779,563     $ 957,096  

Distribution fee revenue

    86,562       75,000  

Total revenue

    1,866,125       1,032,096  
                 

Costs of sales

    673,334       406,721  

Gross profit

    1,192,791       625,375  
                 

Operating expenses

               

Selling, general and administrative

    1,567,223       1,165,517  

Total operating expenses

    1,567,223       1,165,517  
                 

Loss from operations

    (374,432 )     (540,142 )
                 

Other income (expense)

               

Interest income (expense), net

    (51,099 )     409  

Other income

    603       1,814  

Total other income (expenses)

    (50,496 )     2,223  
                 

Net loss

  $ (424,928 )   $ (537,919 )
                 

Loss per common share

         

Basic and diluted

  $ (0.01 )   $ (0.01 )
                 

Weighted average common shares outstanding

         

Basic and diluted

    48,472,374       47,539,384  

 

 

 

NUO THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   

Nine Months

ended

September 30,

2026

   

Nine Months

ended

September 30,

2025

 

Revenue

               

Product sales

  $ 4,694,782     $ 2,066,679  

Distribution fee revenue

    242,444       150,000  

Total revenue

    4,937,226       2,216,679  
                 

Costs of sales

    1,724,681       687,092  

Gross profit

    3,212,545       1,529,587  
                 

Operating expenses

               

Selling, general and administrative

    4,199,995       3,466,898  

Total operating expenses

    4,199,995       3,466,898  
                 

Loss from operations

    (987,450 )     (1,937,311 )
                 

Other income (expense)

               

Interest income (expense), net

    (340,447 )     (33 )

Other income

    6,902       3,608  

Total other income (expenses)

    (333,545 )     3,575  
                 

Net loss

  $ (1,320,995 )   $ (1,933,736 )
                 

Loss per common share

         

Basic and diluted

  $ (0.03 )   $ (0.04 )
                 

Weighted average common shares outstanding

         

Basic and diluted

    48,389,216       47,062,186  

 

 

Filing Exhibits & Attachments

5 documents

Keep reading